Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
Eligible for screening study DCP 001
Completion of Pre-Registration QOLs is required after consent, prior to registration. Please see study documents.
